Genentech’s PFS Data May Help Inavolisib Compete In PI3KCA-Mutated Breast Cancer
Inavolisib meets statistical significance for progression-free survival in HR+/HER2- advanced breast cancer with a PI3KCα mutation, which could set up competition with Piqray, Ibrance and Kisqali.